Alterations in the Activity of Spinal and Thalamic Opioid Systems in a Mice Neuropathic Pain Model

Rojewska, Ewelina and Wawrzczak-Bargiela, Agnieszka and Szűcs, Edina and Benyhe, Sándor and Starnowska, Joanna and Mika, Joanna and Przewlocki, Ryszard and Przewlocka, Barbara (2018) Alterations in the Activity of Spinal and Thalamic Opioid Systems in a Mice Neuropathic Pain Model. NEUROSCIENCE, 390. pp. 293-302. ISSN 0306-4522

Preview

Text RojewskaNeuroscience2018manu.pdf Download (1MB) | Preview

Abstract

Clinical studies have reported lower effectivity of opioid drugs in therapy of neuropathic pain. Therefore, to determine the changes in endogenous opioid systems in this pain more precisely, we have studied the changes in the pain-related behavior on days 1, 14, and 28 following a chronic constriction injury (CCI) to the sciatic nerve in mice. In parallel, we have studied the changes of mu-(MOP), delta-(DOP) and kappa-(KOP) receptors, proenkephalin (PENK) and prodynorphin (PDYN) mRNA levels, as well as GTP gamma S binding of opioid receptors on the ipsi- and contralateral parts of the spinal cord and thalamus on the 14th day following CCI, as on this day the greatest manifestation of pain-related behavior was observed. On ipsilateral spinal cord, the decrease in MOP/DOP/KOP receptor and increase in PDYN/PENK mRNA expression was observed. In thalamus, MOP/DOP/KOP receptor expression decreased contralaterally. On ipsilateral side, there were no changes in PDYN/PENK or DOP/KOP receptor expression, but MOP mRNA decreased. The spinal GTP gamma S binding of MOP/DOP/KOP receptor ligands decreased on the ipsilateral side, yet the effect was less pronounced for DOP receptor ligands. In thalamus, a decrease was observed on the contralateral side for all opioid receptor ligands, especially for DOP ligand. A less pronounced decrease in GTP gamma S binding of spinal DOP ligands may indicate a weaker stimulation of ascending nociceptive pathways, which could explain the absence of decreased activity of DOP receptor ligands in neuropathy. These findings may suggest that drugs with a higher affinity for the DOP receptor will perform better in neuropathic pain. (C) 2018 Published by Elsevier Ltd on behalf of IBRO.

Actions (login required)

Edit Item